Status:
COMPLETED
Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer
Lead Sponsor:
Asan Medical Center
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy and safety of bevacizumab/capecitabine/oxaliplatin combination in metastatic or recurrent Korean colorectal cancer.
Eligibility Criteria
Inclusion
- Histologically or cytologically documented colorectal adenocarcinoma
- ECOG performance status of 2 or lower
- Adequate bone marrow function
- Adequate kidney function
- Adequate liver function
- Informed consent
Exclusion
- Major surgical procedure or significant traumatic injury within 28 days prior to study treatment start
- Known allergy to study drugs
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00378066
Start Date
August 1 2006
End Date
October 1 2008
Last Update
January 23 2013
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Center
Goyang, South Korea
2
Asan Medical Center
Seoul, South Korea
3
Samsung Medical Center
Seoul, South Korea
4
Seoul National University Hospital
Seoul, South Korea